Jesús Esteban-Hernandez

Prof. Jesús Esteban-Hernandez

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2010 in Vaccine
Verified
Journal Article
Closed access
RGRodrigo Jiménez Garcia
Rodrigo Jiménez Garcia
VHValentín Hernández-Barrera
Valentín Hernández-Barrera
Ana Lopez-de-AndresAna Lopez-de-Andres
Ana Lopez-de-Andres
IJIsabel Jimenez-Trujillo
Isabel Jimenez-Trujillo
JEJesús Esteban-Hernandez
Jesús Esteban-Hernandez
PCPILAR CARRASCO-GARRIDO
PILAR CARRASCO-GARRIDO

1 June 2016 in Journal of Stroke and Cerebrovascular Diseases
Verified
Journal Article
Closed access
NMNuria Muñoz-Rivas
Nuria Muñoz-Rivas
MMManuel Méndez-Bailón
Manuel Méndez-Bailón
VHValentín Hernández-Barrera
Valentín Hernández-Barrera
JMJavier de Miguel-Díez
Javier de Miguel-Díez
RGRodrigo Jiménez Garcia
Rodrigo Jiménez Garcia
Ana Lopez-de-AndresAna Lopez-de-Andres
Ana Lopez-de-Andres

29 December 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Nuria Muñoz-RivasNuria Muñoz-Rivas
Nuria Muñoz-Rivas
MMManuel Méndez-Bailón
Manuel Méndez-Bailón
VHValentín Hernández-Barrera
Valentín Hernández-Barrera
JMJavier de Miguel-Díez
Javier de Miguel-Díez
RGRodrigo Jiménez Garcia
Rodrigo Jiménez Garcia
Ana Lopez-de-AndresAna Lopez-de-Andres
Ana Lopez-de-Andres
Type 2 Diabetes (T2DM) is the most rapidly increasing risk factor for ischemic stroke. We aimed to compare trends in outcomes for ischemic stroke in people with or without diabetes in Spain between 2003 and 2012. We selected all patients hospitalized for ischemic stroke using national hospital discharge data. We evaluated annual incident rates stratified by T2DM status. We analyzed trends in the use of diagnostic and therapeutic procedures, patient comorbidities, and in-hospital outcomes. We calculated in-hospital mortality (IHM), length of hospital stay (LOHS) and readmission rate in one month after discharge. Time trend on the incidence of hospitalization was estimated fitting Poisson regression models by sex and diabetes variables. In-hospital mortality was analyzed using logistic regression models separate for men and women. LOHS were compared with ANOVA or Kruskal-Wallis when necessary. We identified a total of 423,475 discharges of patients (221,418 men and 202,057 women) admitted with ischemic stroke as primary diagnosis. Patients with T2DM accounted for 30.9% of total. The estimated incidence rates of discharges increased significantly in all groups. The incidence of hospitalization due to stroke (with ICD9 codes for stroke as main diagnosis at discharge) was higher among those with than those without diabetes in all the years studied. T2DM was positively associated with ischemic stroke with an adjusted incidence rate ratio (IRR) of 2.27 (95% CI 2.24–2.29) for men and 2.15 (95%CI 2.13–2.17) for women. Over the 10 year period LOHS decreased significantly in men and women with and without diabetes. Readmission rate remained stable in diabetic and non diabetic men (around 5%) while slightly increased in women with and without diabetes. We observed a significant increase in the use of fibrinolysis from 2002–2013. IHM was positively associated with older age in all groups, with Charlson Comorbidity Index > 3 and atrial fibrillation as risk factors. The IHM did not change significantly over time among T2DM men and women ranging from 9.25% to 10.56% and from 13.21% to 14.86%, respectively; neither did among non-diabetic women. However, in men without T2DM IHM decreased significantly over time. Diabetes was associated to higher IHM only in women (OR 1.07; 95% CI, 1.05–1.11). Our national data show that incidence rate of ischemic stroke hospitalization increased significantly during the period of study (2003–2012). People with T2DM have more than double the risk of ischemic stroke after adjusting for other risk factors. Women with T2DM had poorer outcomes- IHM and readmission rates- than diabetic men. Diabetes was an independent factor for IHM only in women.

18 January 2012 in Clinical & Experimental Allergy
Verified
Journal Article
Closed access
PDF file
MTMiguel Angel Tejedor-Alonso
Miguel Angel Tejedor-Alonso
MMM. Moro Moro
M. Moro Moro
MGM. V. Múgica García
M. V. Múgica García
JEJesús Esteban-Hernandez
Jesús Esteban-Hernandez
AIA. Rosado Ingelmo
A. Rosado Ingelmo
AMA. Hernández Merino
A. Hernández Merino

1 February 2005 in Vaccine
Verified
Journal Article
Closed access
JJJ.R. De Juanes
J.R. De Juanes
AGA. Gil
A. Gil
MSM. San-Martín
M. San-Martín
AGA. González
A. González
JEJesús Esteban-Hernandez
Jesús Esteban-Hernandez
ACA. García de Codes
A. García de Codes

1 September 2003 in Vaccine
Verified
Journal Article
Closed access
RGRodrigo Jiménez Garcia
Rodrigo Jiménez Garcia
ALAmparo Larrauri
Amparo Larrauri
PCPILAR CARRASCO-GARRIDO
PILAR CARRASCO-GARRIDO
JEJesús Esteban-Hernandez
Jesús Esteban-Hernandez
LGLuis Ignacio Gómez-López
Luis Ignacio Gómez-López
ÁGÁngel Gil
Ángel Gil